Cue Biopharma Inc (CUE) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Cue Biopharma Inc (CUE) following the 2026 Q2 hedge fund 13F filings?

As of today, CUE has moved -24.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.4% for the XLV sector ETF — an outperformance of -26.8%. Since the quarter end (June 30, 2026), CUE gained -18.0% vs +8.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Cue Biopharma Inc (CUE)

1 + Investors. Track Smart Money conviction in CUE. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CUE

Based on 2 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their CUE positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🔻

Below peak — only 3% of 3.0Y high

3% of all-time peak

Only 2 funds hold CUE today versus a peak of 76 funds at 2023 Q4 — just 3% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.

📉

Outflows — 96% fewer funds vs a year ago

fund count last 6Q

45 fewer hedge funds hold CUE compared to a year ago (-96% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.

🔴

Heavy selling pressure — only 2% buying

1 buying51 selling

Last quarter: 51 funds sold vs only 1 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

⚠️

Fewer new buyers each quarter (-12 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 9 → 7 → 13 → 1. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

50% of holders stayed for 2+ years

■ 50% conviction (2yr+) ■ 0% medium ■ 50% new

1 out of 2 hedge funds have held CUE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

➡️

Steady discovery — ~1 new funds/quarter

8 → 9 → 7 → 13 → 1 new funds/Q

New funds entering each quarter: 9 → 7 → 13 → 1. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 50% veterans vs 50% newcomers

■ 50% veterans ■ 0% 1-2yr ■ 50% new

Entry-cohort mix of 2 holders: 1 (50%) are 2+ year veterans, 0 entered 1–2 years ago, and 1 (50%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

📋

Smaller funds dominant — 0% AUM from top-100

0% from top-100 AUM funds

0 of 2 holders rank in the top 100 by AUM, but together hold only 0% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

3.6

out of 10

Low Exit Risk

Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	1	52	-98.08%
13F Shares	100	21M	-100.0%
Total Value	$55	$5M	-100.0%
New Positions	0	13	-13
Increased Positions	0	5	-5
Closed Positions	51	9	+42
Reduced Positions	0	10	-10
Total Calls	0	0	-
Total Puts	0	1	-100.0%
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

-98.08%

13F Shares

100

21M

-100.0%

Total Value

$55

$5M

-100.0%

New Positions

-13

Increased Positions

-5

Closed Positions

+42

Reduced Positions

-10

Total Calls

Total Puts

-100.0%

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

1 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CUE. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CUE holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Lion Point Capital, LP	7.99%	52,928	$1.7M
2	Bleichroeder LP	2.09%	370,682	$11.7M
3	Squadron Capital Management LLC	0.49%	50,000	$1.6M
4	Tetragon Partners GP Ltd	0.47%	93,819	$3.0M
5	Stempoint Capital LP	0.36%	66,995	$2.1M
6	Ikarian Capital, LLC	0.35%	104,364	$3.3M
7	Diadema Partners LP	0.19%	48,369	$1.5M
8	Persistent Asset Partners Ltd	0.12%	12,332	$389K
9	ADAR1 Capital Management, LLC	0.08%	55,193	$1.7M
10	Seven Fleet Capital Management LP	0.06%	10,702	$338K
11	Driehaus Capital Management LLC	0.05%	292,144	$9.2M
12	Texas Capital Bank Wealth Management Services Inc	0.04%	22,881	$722K
13	Advisory Research Inc	0.03%	8,573	$271K
14	Boothbay Fund Management, LLC	0.01%	31,459	$993K
15	Angeles Wealth Management, LLC	0.01%	7,000	$221K
16	Robertson Stephens Wealth Management, LLC	0.01%	11,133	$351K
17	Tower Research Capital LLC (TRC)	0.00%	869	$27K
18	Renaissance Technologies LLC	0.00%	14,689	$464K
19	Gleason Group, Inc.	0.00%	200	$6K
20	NFSG Corp	0.00%	99	$3K
21	Tidemark, LLC	0.00%	50	$2K
22	Stifel Financial Corp	0.00%	8,218	$259K
23	SBI Securities Co., Ltd.	0.00%	300	$9K
24	Golden State Wealth Management, LLC	0.00%	66	$2K
25	Vanguard Fiduciary Trust Co	0.00%	24,476	$772K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Cue Biopharma Inc (CUE)

What does the Smart Money Trend signal show for CUE?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their CUE positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CUE?

Heavy selling pressure — only 2% buying: Last quarter: 51 funds sold vs only 1 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for CUE holders?

Smaller funds dominant — 0% AUM from top-100: 0 of 2 holders rank in the top 100 by AUM, but together hold only 0% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held CUE?

50% of holders stayed for 2+ years: 1 out of 2 hedge funds have held CUE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Cue Biopharma Inc (CUE) following the 2026 Q2 hedge fund 13F filings?

As of today, CUE has moved -24.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.4% for the XLV sector ETF — an outperformance of -26.8%. Since the quarter end (June 30, 2026), CUE has gained -18.0% vs +8.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Cue Biopharma Inc (CUE)

Smart Money Signals — CUE

Selling streak — 1 quarter in a row

Below peak — only 3% of 3.0Y high

Outflows — 96% fewer funds vs a year ago

Heavy selling pressure — only 2% buying

Fewer new buyers each quarter (-12 vs last Q)

50% of holders stayed for 2+ years

Steady discovery — ~1 new funds/quarter

Veteran-anchored — 50% veterans vs 50% newcomers

Smaller funds dominant — 0% AUM from top-100

Institutional Sentiment Summary — CUE

Hedge Fund Ownership: CUE

Market Analysis: CUE

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CUE

Is It Too Late to Buy Cue Biopharma Inc (CUE) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: CUE

Statistics: CUE

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Cue Biopharma Inc (CUE)

Welcome to 13Foresight!